Marbán. and a started very Dr. the been has a very we've collaboration year. here the deep, of Yes, broad general we over you, that it approach that past clear presentation with at Capricor been pursuing Thank Hopkins
We with in to to the basic real actual are clinical our both excited also and expand terms problems. be allows research, horizons but targeting working it of of exosome us to Capricor rules in applying and very and production biogenesis world
in of the make essentially formulation, so high-throughput that need is there's the approach sure that efficient the exosome Our loading exosomes, way targeting. we manufacturing, and an great production here, can outlined them, this develop a in slide we platform the the optimize to of the
a talking that data bit about delivery. exosome start of about utility to been the a of little platforms small is piece going I'm what so And we've collecting RNA general with for the
might of right you to exosomes how LNPs. be other So one the of or compare away RNA delivery platforms the nanoparticles questions thinking is specifically that lipid
you that a piece that to And variety very show a of experiments our wide I'm of data on going undertaken so we've small issue.
The adverse weight in of the animals. can animals, see first we reduction engender nanoparticles LNP for being lead three here short figure And have red in a this not gross they're squares detected we And weight to of can LNPs equal weight the the is that equal And of period the change a the vesicles thing to time, indicative not numbers that the upon equal that are effect It kind any injected. exosome is for seen reduction response day animals. show after weighing the quite that causes animals of black doesn't I'd weight mean days what injections of The effects an of animals true treatment numbers examination zero. of be over of reflects numbers adverse in a horrible bit injection. What is that are injections, a injection lipid of of is visual to brewing very is is dots it treatment. feel toxicity data marker of of but a animals on here, of and there's like weight to exosomes any useful a necessarily off. or
injecting to just the number with causes is animals no animals. equal LNPs animals injecting exosomes. some this There's of distress with So an effect,
of we analysis. measuring real not eat for animals these by very And in as that to understand. is know key the feel slide. just shown in But much. when easy we And us a that's tend histological detailed Now we looking – to all well, feel animals, weights thing all don't this
exosomes. true been or but these animals each group. animals lung, analysis, it little Now the make diaphragm, through of and a same kidney, are here panels row their on are that gland, to histological animals for same And an samples let me have spleen, animals examined of age, multiple go there's it. on these from And liver, is intestine, with independent control brain. control injected histological heart, a were in were done all The based normal. lot salivary simpler, The top totally morphology mice, and
we're them back administered in leading injecting an of same injected animals same report the And with equal similar histological the in the for all said being the exosomes of or vaccines. came are be So again, exosome animals LNPs. number in that LNPs In with injected these are with tissues animals the some those animals. LNPs normal The were cannot same injecting or LNPs. either all the saline that of as basic very composition number
of was was most their tissues, in most there in the while abnormalities no there So abnormality in spleen. an animals
high increase And LNP the an a paired nonspecific in was the of hand-in-hand amount animals. pulp of injected of in sort a seen that in data loss in specifically indication was the red the this we what goes and these with – animals weight saw spleen increase So pulp is the red inflammation.
expected any exosomes this pieces numbers effects. has people is transfusion associated transplantation So showing what and nearly of that large of has two that into entirely not because that And demonstrated the to is a exosomes we're sum adverse as medicine adverse injections effects. is no up delivery massive exosomes of amounts of with these data of you century of and
basically already we're kind the what medicine knows. just assay. reproducing this LNPs by contrast, are So of In inflammatory injection mildly of
which to they of effects I'm studies can as exosomes mRNAs. you just Well, just question compare is, show that are the a how we show little that's you vehicle terms we've these comparing in many the that. a so next vehicles, data. have snapshot going those with do delivery can Again, this. bit of we a of alone? on delivery the on And deliver data as one functionally well, What the done vehicle. vehicles and many, little LNPs efficiency the today of And
at grown luciferase, culture. enzyme, that looking cells of in So you're are what on is a that's the assayed here expression a light-emitting
delivering in So a enzyme, mRNA an into as obviously, luciferase these though can we're we a any light. to do for synthesize cells. What can vitro, that living a that we is cells, used encodes these RNA emit how don't can they normally marker messenger efficiently be
So the get RNA. present have again, RNA The and this exosomes enzyme has with into protein that cytoplasm of not a have can cell. of do not is degree in do the light. this to activity. into The that active, LNPs it has activity a protein, the has so translated to and activity. a to enzymatically so high the The be cells emit fidelity, strictly particles, not is done It be
emitting substrate. it's when So of once capable made, the it's given light
it what There's enzyme done present, DTZ, don't the the light and control the control the you add substrate. cells on is emitted. is called So you substrate a we we've can responds left, is see – far here have those bar if that's cells to
activity. to the are That's on emission. substrate control the cells, zero add the why bottom light no at all at circles control those there's you right black If
do Now, same per of we of particles But this XXth emitting good of the RNA enzyme. – get when tens amount light lipid mil standard a expression into of amount when load we we emission, exact amount the more a nanoparticles, as do we're experiment, of it's cytoplasm turned LNPs, of into human efficiently delivering same light get into the which parallel that more the RNA, being And RNA same numbers the functional enzyme. cells. of we means exosomes constant
is of administration therapeutic showed to more effect difference two say, when we diseases. that, this middle It's adverse with you to many, delivering and going administration. have see, really can that you is you important difference. now see amounts on get when that high mRNA as lipid a go many tenfold mRNA dose So is those is that a cure, you've happens now to graph, the the dramatic. what exosome-mediated delivery RNA carry. of And exosomes in nanoparticles, LNP-mediated RNA dosed to bars What large the genetic particularly by And you're high delivery, RNA the lot expression times than in where they of be for between an dose are order
And the where to delivery exosome-mediated in culture, limit encodes vivo. slide, seems experiment, just indication RNA going really you light you tissue exosomes, I to delivery. a same that treated. picture some show in in light-emitting cells a vivo of of coming but terms and of there upper take have point, the that I'm important the human this So in be know in we've what a don't is see culture a protein, sort often data mRNA we're of you next yes, we the mean, this LNP-mediated of in you a animals which I is And loaded out in RNA light-emitting with is mRNA that very going very tissue to actually show protein an – you'll on good what see
see no on the you injections. couple are that left of exosome animals received So what
may have been see called these DTZ. normal loaded with just substrate only they all these enzyme, mice receive mice, background this the not of a of are light-emitting animals alive. any these exosomes, and And the injected for So mRNA it's you pictures
exosome to On encodes into and protein being our the loaded light-emitting day the animals, with a into deliver that are before. And then day that turned the then mRNA cells active. where injected that that this folding it's RNA mRNA the a the enzyme, that the were so and enzymatically after mRNA of animals properly, right protein pair to of exosomes, RNA a allow
the that substrate animals. then these comes to where inject animals, enzymes the of for substrate you now enzyme a light the gets into and is, out If
you expression processes getting different real you're think there the about the lumens that looks program would protein of it's occur formulations. on you're and of showing or our it this how And emitted it's development in animal of development a vaccine and time this time idea these kind brightest animal a Anyway, although RNA, biochemical, gene real regions biological all the like looking animal, the evidence expression an red, are version just in not from vivo so coding is is what of any many on the So in gives just, therapeutic our same minute of exposure or formulations. therapeutic RNA second so. are per in and those areas light emission scales this it right being a I live our in a cell light program, from exosome loaded not is a vaccine is molecular name, of
just directly proteins same We replacement out exosome very not platform functional but our shows are any but have course the this there directly therapy that relevant viral enzyme not or So for can do type to or of can of deliver gene therapy enzymes. is And are kind this can paradigms that enzymes, pulpit, functional injections. that you protein, enzyme vectors RNAs. thing of based with profitably
we last protein, not research which but vaccine reiterate we vaccine. to and on very immunity also summer to that nucleocapsid. immunity wanted virus, of but we to when called level, that on performed we generate level exosome little vaccine a which other the did make broader late structural that have wanted actually to a a June, a spike of drive the and could the wanted a protein We non-toxic the all antibody achieved. SARS-CoV-X a drive vaccine, I early is cellular in the this, formulations, bit to based experiments work mRNA major earliest just safe would And manufacturing we to at point want just sure say about we Now, view, just our we started SARS-CoV-X
synthesize, we those we same them and So we we two works, use responses the to mice, formulated we at mRNA time exosomes into the responses that in get that proteins. both multiplexed immune to confirms formulations elicit immune and have data approach mRNAs the
had elicited on we little the very as immune antibody remained immune where RNA nucleocapsid. amount say responses, responses early anti-nucleocapsid but now generated CDX-positive through we now, came vaccination basically constant end our that get after dosing cellular CDX-positive of nucleocapsid both at in only that in got much we decline with we we're in up up And to time, responses terms strong the our well. did below loading optimize both vaccination and well this But even formulations, show studies yet Now the that had that as just overall antigen that spike that – first in antigen of the vaccine testing significantly, of out not these is responses, has strong in very antibody low, are very preface data delivering will we the that to strong this, improved a to here to at RNA quite even efficiency micrograms our is to shows had getting responses early and where Not very optimized better also formulations. been time study. protein only and C I’ll study, And and we that the by B line beyond and from we very this that the I'm XX and going immune you immune saying in micrograms, right responses I A study, panel our in we performed. our then relative this deliver, diagram X the very demonstrates XX antibody spike early out first our of panel platform that of expression the vaccine to we top anti-spike and to our we're design and the and the shown our protein. we were regimen dates micrograms
approach And but other to more is in snapshot studies ongoing we're really just therapeutics of not is excited SARS-CoV-X this importantly, our to limited And so vaccines. just what approach, our development. a is our vaccines,
And words so, couple just that. going just I'm a about to of say
we very against vaccines. in We're exosome Our platform. the RNA And we the vaccines, very a generating to SARS-CoV-X interesting fight hope view therapeutics for are that of help be with but with are has fantastic also addressed interested quickly RNA research very a very optimizing that candidate to troubleshooting, the we developmental in that reiterate issues the vaccines is vaccine process want are other also development program on optimized of to studies the our which the and delivery. I vaccines in
but to Capricor, not clinically those a number and generating of of towards emit in of, that much it very turn platform to animal that online middle projects our defects this prelude delivery demonstrate the just where repair mice collaboration with week. in to a a to and we Baltimore, developmental results say bioRxiv on potential we I focus now delivering in animals, therapies. because we I'll at And therapeutics, colleagues light are we at bring have do present. useful genetic posted that they RNAs, the earlier working functional from think the strong back the also just research you back in looked earlier, we've And sums models have what have about at in been area at up pretty that mRNA We to Dr. want exosome that as were collaboration the And I Marbán. really to here I and
